Other examples include the nonspecific JAK1/2 inhibitors ruxolitinib and fedratinib, which are used to treat myeloproliferative neoplasms, and selinexor, which inhibits transport of proteins from the nucleus to cytoplasm, decreases cell proliferation, and is effective in multiple myeloma.